• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在酪氨酸激酶激活的白血病中,c-MYC通过增加非同源末端连接替代因子LIG3和PARP1的转录来产生修复错误。

c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.

作者信息

Muvarak Nidal, Kelley Shannon, Robert Carine, Baer Maria R, Perrotti Danilo, Gambacorti-Passerini Carlo, Civin Curt, Scheibner Kara, Rassool Feyruz V

机构信息

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland. Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland.

Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland. The Center for Stem Cell Biology and Regenerative Medicine, University of Maryland School of Medicine, Baltimore, Maryland.

出版信息

Mol Cancer Res. 2015 Apr;13(4):699-712. doi: 10.1158/1541-7786.MCR-14-0422. Epub 2015 Mar 31.

DOI:10.1158/1541-7786.MCR-14-0422
PMID:25828893
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4398615/
Abstract

UNLABELLED

Leukemias expressing the constitutively activated tyrosine kinases (TK) BCR-ABL1 and FLT3/ITD activate signaling pathways that increase genomic instability through generation of reactive oxygen species (ROS), DNA double-strand breaks (DSB), and error-prone repair. The nonhomologous end-joining (NHEJ) pathway is a major pathway for DSB repair and is highly aberrant in TK-activated leukemias; an alternative form of NHEJ (ALT-NHEJ) predominates, evidenced by increased expression of DNA ligase IIIα (LIG3) and PARP1, increased frequency of large genomic deletions, and repair using DNA sequence microhomologies. This study, for the first time, demonstrates that the TK target c-MYC plays a role in transcriptional activation and subsequent expression of LIG3 and PARP1 and contributes to the increased error-prone repair observed in TK-activated leukemias. c-MYC negatively regulates microRNAs miR-150 and miR-22, which demonstrate an inverse correlation with LIG3 and PARP1 expression in primary and cultured leukemia cells and chronic myelogenous leukemia human patient samples. Notably, inhibition of c-MYC and overexpression of miR-150 and -22 decreases ALT-NHEJ activity. Thus, BCR-ABL1 or FLT3/ITD induces c-MYC expression, leading to genomic instability via augmented expression of ALT-NHEJ repair factors that generate repair errors.

IMPLICATIONS

In the context of TK-activated leukemias, c-MYC contributes to aberrant DNA repair through downstream targets LIG3 and PARP1, which represent viable and attractive therapeutic targets.

摘要

未标记

表达组成型激活酪氨酸激酶(TK)BCR-ABL1和FLT3/ITD的白血病激活信号通路,通过产生活性氧(ROS)、DNA双链断裂(DSB)和易出错修复增加基因组不稳定性。非同源末端连接(NHEJ)途径是DSB修复的主要途径,在TK激活的白血病中高度异常;另一种形式的NHEJ(ALT-NHEJ)占主导,表现为DNA连接酶IIIα(LIG3)和PARP1表达增加、大基因组缺失频率增加以及使用DNA序列微同源性进行修复。本研究首次证明,TK靶点c-MYC在LIG3和PARP1的转录激活及随后的表达中起作用,并导致在TK激活的白血病中观察到的易出错修复增加。c-MYC负向调节微小RNA miR-150和miR-22,它们在原代和培养的白血病细胞以及慢性粒细胞白血病患者样本中与LIG3和PARP1表达呈负相关。值得注意的是,抑制c-MYC以及过表达miR-150和-22可降低ALT-NHEJ活性。因此,BCR-ABL1或FLT3/ITD诱导c-MYC表达,通过增加产生修复错误的ALT-NHEJ修复因子的表达导致基因组不稳定。

启示

在TK激活的白血病背景下,c-MYC通过下游靶点LIG3和PARP1促进异常DNA修复,这两个靶点是可行且有吸引力的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e2/4398615/94884a7d13e8/nihms653579f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e2/4398615/39453438a3e1/nihms653579f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e2/4398615/e7f69a73fb63/nihms653579f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e2/4398615/a53b41d9eba6/nihms653579f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e2/4398615/b8ed46a15da6/nihms653579f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e2/4398615/c4fc4c37b858/nihms653579f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e2/4398615/94884a7d13e8/nihms653579f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e2/4398615/39453438a3e1/nihms653579f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e2/4398615/e7f69a73fb63/nihms653579f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e2/4398615/a53b41d9eba6/nihms653579f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e2/4398615/b8ed46a15da6/nihms653579f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e2/4398615/c4fc4c37b858/nihms653579f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17e2/4398615/94884a7d13e8/nihms653579f6.jpg

相似文献

1
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.在酪氨酸激酶激活的白血病中,c-MYC通过增加非同源末端连接替代因子LIG3和PARP1的转录来产生修复错误。
Mol Cancer Res. 2015 Apr;13(4):699-712. doi: 10.1158/1541-7786.MCR-14-0422. Epub 2015 Mar 31.
2
Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.针对酪氨酸激酶抑制剂耐药性慢性髓性白血病中异常的 DNA 双链断裂修复。
Oncogene. 2013 Apr 4;32(14):1784-93. doi: 10.1038/onc.2012.203. Epub 2012 May 28.
3
Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma.替代性非同源末端连接途径成分是高危神经母细胞瘤的治疗靶点。
Mol Cancer Res. 2015 Mar;13(3):470-82. doi: 10.1158/1541-7786.MCR-14-0337. Epub 2015 Jan 6.
4
Marked contribution of alternative end-joining to chromosome-translocation-formation by stochastically induced DNA double-strand-breaks in G2-phase human cells.在G2期人类细胞中,随机诱导的DNA双链断裂通过替代末端连接对染色体易位形成的显著贡献。
Mutat Res Genet Toxicol Environ Mutagen. 2015 Nov;793:2-8. doi: 10.1016/j.mrgentox.2015.07.002. Epub 2015 Jul 4.
5
Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks.慢性髓性白血病中WRN和DNA连接酶IIIα的上调:对DNA双链断裂修复的影响
Blood. 2008 Aug 15;112(4):1413-23. doi: 10.1182/blood-2007-07-104257. Epub 2008 Jun 4.
6
Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.聚(ADP-核糖)聚合酶PARP1和PARP2与DNA双链断裂修复途径的常见和独特遗传相互作用。
DNA Repair (Amst). 2016 Sep;45:56-62. doi: 10.1016/j.dnarep.2016.06.001. Epub 2016 Jun 16.
7
Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy.表达 FLT3/ITD 突变的细胞表现出通过替代 NHEJ 途径产生的修复错误增加:对基因组不稳定性和治疗的影响。
Blood. 2010 Dec 9;116(24):5298-305. doi: 10.1182/blood-2010-03-272591. Epub 2010 Aug 31.
8
CRISPR/Cas9-Induced Double-Strand Break Repair in Arabidopsis Nonhomologous End-Joining Mutants.CRISPR/Cas9诱导的拟南芥非同源末端连接突变体中的双链断裂修复
G3 (Bethesda). 2017 Jan 5;7(1):193-202. doi: 10.1534/g3.116.035204.
9
Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.替代性非同源末端连接通路蛋白作为 MYCN 癌基因活性在人神经嵴干细胞分化中的组成部分:对神经母细胞瘤发生的影响。
Cell Death Dis. 2017 Dec 13;8(12):3208. doi: 10.1038/s41419-017-0004-9.
10
BCR/ABL stimulates WRN to promote survival and genomic instability.BCR/ABL 激活 WRN 促进生存和基因组不稳定性。
Cancer Res. 2011 Feb 1;71(3):842-51. doi: 10.1158/0008-5472.CAN-10-1066. Epub 2010 Dec 1.

引用本文的文献

1
Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers.多发性骨髓瘤中PAN细胞焦亡特征的综合机器学习分析确定了预后和免疫治疗生物标志物。
Sci Rep. 2025 Jul 2;15(1):22478. doi: 10.1038/s41598-025-06376-0.
2
Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment.利用替代性末端连接的转录调控来预测癌症治疗。
NAR Cancer. 2025 Mar 7;7(1):zcaf007. doi: 10.1093/narcan/zcaf007. eCollection 2025 Mar.
3
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

本文引用的文献

1
Mechanisms of oncogenic chromosomal translocations.致癌染色体易位的机制。
Ann N Y Acad Sci. 2014 Mar;1310:89-97. doi: 10.1111/nyas.12370. Epub 2014 Feb 16.
2
Targeting components of the alternative NHEJ pathway sensitizes KRAS mutant leukemic cells to chemotherapy.靶向非同源末端连接修复途径的组分可使 KRAS 突变型白血病细胞对化疗敏感。
Blood. 2014 Apr 10;123(15):2355-66. doi: 10.1182/blood-2013-01-477620. Epub 2014 Feb 6.
3
MicroRNA-regulated pathways in hematological malignancies: how to avoid cells playing out of tune.
FGF/FGFR/c-Myc 轴作为多发性骨髓瘤有前景的治疗靶点。
J Exp Clin Cancer Res. 2024 Nov 1;43(1):294. doi: 10.1186/s13046-024-03217-2.
4
Study of PARP inhibitors for breast cancer based on enhanced multiple kernel function SVR with PSO.基于粒子群优化的增强多核函数支持向量回归机的PARP抑制剂治疗乳腺癌的研究
Front Pharmacol. 2024 Feb 2;15:1257253. doi: 10.3389/fphar.2024.1257253. eCollection 2024.
5
PARP1 Characterization as a Potential Biomarker for p190+ Acute Lymphoblastic Leukemia.PARP1作为p190 +急性淋巴细胞白血病潜在生物标志物的特征分析
Cancers (Basel). 2023 Nov 22;15(23):5510. doi: 10.3390/cancers15235510.
6
Dysregulation of Non-Coding RNAs: Roles of miRNAs and lncRNAs in the Pathogenesis of Multiple Myeloma.非编码RNA的失调:微小RNA和长链非编码RNA在多发性骨髓瘤发病机制中的作用
Noncoding RNA. 2023 Nov 3;9(6):68. doi: 10.3390/ncrna9060068.
7
Knockdown of ASF1B inhibits cell proliferation, migration, invasion and cisplatin resistance in gastric cancer through the Myc pathway.ASF1B的敲低通过Myc途径抑制胃癌细胞的增殖、迁移、侵袭和顺铂耐药性。
Oncol Lett. 2023 Apr 20;25(6):242. doi: 10.3892/ol.2023.13828. eCollection 2023 Jun.
8
Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches.急性髓系白血病中FLT3的治疗靶点:现状与新方法
Onco Targets Ther. 2022 Nov 30;15:1449-1478. doi: 10.2147/OTT.S384293. eCollection 2022.
9
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin.通过类黄酮瑞香素利用多发性骨髓瘤的 DNA 连接酶 III 依赖性。
J Transl Med. 2022 Oct 22;20(1):482. doi: 10.1186/s12967-022-03705-z.
10
Activating STING1-dependent immune signaling in mutant and wild-type acute myeloid leukemia.在突变型和野生型急性髓系白血病中激活 STING1 依赖性免疫信号通路。
Proc Natl Acad Sci U S A. 2022 Jul 5;119(27):e2123227119. doi: 10.1073/pnas.2123227119. Epub 2022 Jun 27.
血液系统恶性肿瘤中 microRNA 调控的通路:如何避免细胞奏出不和谐的曲调。
Int J Mol Sci. 2013 Oct 18;14(10):20930-53. doi: 10.3390/ijms141020930.
4
Targeted cancer therapeutics: biosynthetic and energetic pathways characterized by metabolomics and the interplay with key cancer regulatory factors.靶向癌症治疗:通过代谢组学表征的生物合成和能量途径以及与关键癌症调节因子的相互作用。
Curr Pharm Des. 2014;20(15):2637-47. doi: 10.2174/13816128113199990489.
5
Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.通过基因突变和表达谱鉴定的白血病中靶向 RAD52 诱导的个性化合成致死性。
Blood. 2013 Aug 15;122(7):1293-304. doi: 10.1182/blood-2013-05-501072. Epub 2013 Jul 8.
6
MiR-27a functions as a tumor suppressor in acute leukemia by regulating 14-3-3θ.miR-27a 通过调节 14-3-3θ 在急性白血病中发挥肿瘤抑制作用。
PLoS One. 2012;7(12):e50895. doi: 10.1371/journal.pone.0050895. Epub 2012 Dec 7.
7
Revisiting global gene expression analysis.重新审视全球基因表达分析。
Cell. 2012 Oct 26;151(3):476-82. doi: 10.1016/j.cell.2012.10.012.
8
c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells.c-Myc 是淋巴细胞和胚胎干细胞中表达基因的通用放大器。
Cell. 2012 Sep 28;151(1):68-79. doi: 10.1016/j.cell.2012.08.033.
9
Transcriptional amplification in tumor cells with elevated c-Myc.肿瘤细胞中 c-Myc 升高导致的转录扩增。
Cell. 2012 Sep 28;151(1):56-67. doi: 10.1016/j.cell.2012.08.026.
10
Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.针对酪氨酸激酶抑制剂耐药性慢性髓性白血病中异常的 DNA 双链断裂修复。
Oncogene. 2013 Apr 4;32(14):1784-93. doi: 10.1038/onc.2012.203. Epub 2012 May 28.